We have hosted and curated conversations with leaders to share non-obvious insights and collaborate on solutions. In 2021, we partnered with TechCrunch to host a series of online conversations at their annual Disrupt and Early Stage conferences, to engage with their network of global entrepreneurs. Learn from human & planetary health leaders in our compendium ebook.
Next generation CRISPR platform company Mammoth Biosciences recently shared several milestones as they announced their $195M funding at a $1B+ valuation and partnered with Vertex Pharmaceuticals to create in vivo gene therapies for genetic diseases. We’re honored to have been partnered since the Seed round at Mammoth’s inception through today as they transform healthcare.
GraphWear is leveraging a breakthrough material, inventing a new transistor, and innovating on process to solve a Holy Grail problem. By eliminating our fear of needles, GraphWear will transform how diabetics and pre-diabetics live. And with future targets of their breakthrough platform to other markers in our blood, it has the potential to save billions of lives.
Thoughtless consumption brought us climate change, but it is also true that mindful consumption can get us out of it. In this TechCrunch post, Arvind shares how we can use capitalism to eliminate greenhouse gas emissions worldwide by following the carbon, laying out a roadmap for climate investors seeking to improve planetary health for our generation and the next ones.
Treatments for physical and mental health that involve the brain have historically been slow to market and prohibitively expensive, but a new generation of brain-centered businesses are rewiring the brain to improve our quality of life. In this video, Ursheet joins MedTech Insights to discuss his learnings as an inception-stage investor as well as the future of brain disease treatment.
The lack of innovation around scaling and mass-production is the biggest barrier and threat to the alternative protein industry. In this interview with Future Food-Tech, Arvind shares his perspective on the commercial viability of cell-based meats, food industry trends and more.
